Despite the availability of HER2-targeted therapies, a considerable proportion of HER2+ breast cancers exhibit an aggressive phenotype and eventually relapse due to acquired or intrinsic resistance that enables escape from HER2 inhibition21,24. This evidence concerns the gene ERBB2 and breast carcinoma.